GlaxoSmithKline can market the new Corona vaccine by the end of the year. In the initial tests, the vaccine formula will enter its final stage trial in a few weeks after receiving positive results. This news will bring relief to GSK, which is trying to match its rivals in the race to make Vaccine. At the same time, the company’s chief executive Emma Walmsley will also be able to take a breather after the news, which came under pressure after an investor Elliott Management withdrew the stake in April.
The company has made the vaccine together with its French partner Sanofi. The vaccine was expected to receive regulatory approval in the first half of 2021 but was delayed in December as the vaccine failed to develop a robust immune system in the elderly. GSK said on Monday that the interim results of the Phase-2 trial showed a strong antibody response in people of all adult age groups and no safety concerns were found during this period, after which it cleared the way for the third phase.
The third phase will include 35,000 adults
Roger Kanner, president of the vaccine arm of GSK, said that we believe this vaccine can contribute significantly to the ongoing fight against Corona and to complete our goal of launching it in the third phase soon by the end of the year. Have to start as soon as possible.
Phase III trials are expected to begin in the coming weeks and will include 35,000 adults from different countries. It will also assess the efficacy of two vaccine formulas against variants first encountered in Wuhan (D614) and those found in South Africa (B.1.351).
Britain placed a pre-order of 60 million doses
The pharmaceutical firm said it expected to receive regulatory approval for the vaccine in the fourth quarter of the year. The UK had pre-ordered 60 million doses of the GSK / Sanofi vaccine by December. Talking about the company’s latest shares, GSK shares fell 0.3 per cent to close at 13.66 pounds on Monday.
The postappeared first on .